featured
Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy for Advanced ccRCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: